4D pharma (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announces that it has today conditionally placed with investors 3,797,469 new ordinary shares (the "Placing Shares"), through Zeus Capital Limited as broker to the Company, at a placing price of 790p per ordinary share to raise approximately £30 million before expenses (the "Placing").

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following clinical update on Blautix™, its proprietary live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS).

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following updates on Blautix, its proprietary programme for the treatment of Irritable Bowel Syndrome (IBS) and Thetanix, its proprietary programme for the treatment of Paediatric Crohn's Disease.